Physician profile
Julie U Wu
NPI 1588602957
$12,723.14
in general payments reported to CMS, 2019-2025
56 companies · $1,507 in 2025
The $1,507 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,313 · 2020: $1,284 · 2021: $3,120 · 2022: $1,614 · 2023: $1,813 · 2024: $2,072 · 2025: $1,507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,307 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,306.97 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,230.90 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Biohaven Pharmaceuticals, INC. | $1,219.91 | 2021 | |
| Abbvie INC. | $586.17 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Mannkind Corporation | $577.03 | 2019-2025 | Afrezza |
| Novartis Pharmaceuticals Corporation | $549.94 | 2022-2025 | |
| Astellas Pharma US INC | $518.50 | 2019-2024 | Veozah, Myrbetriq |
| Amgen INC. | $515.09 | 2020-2025 | Repatha, Otezla, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $462.98 | 2021-2025 | |
| Kci USA, INC. | $458.67 | 2019 | |
| Smith+Nephew, INC. | $457.78 | 2019-2024 | Collagenase Santyl |
| Gilead Sciences, INC. | $455.11 | 2023-2025 | |
| Melinta Therapeutics, LLC | $449.13 | 2019-2025 | Kimyrsa, Rezzayo |
| Lilly USA, LLC | $375.83 | 2020-2025 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $368.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.08 | 2019-2025 | Jardiance |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.